CClinicalTrials.gg
CompletedNCT00730366Updated Sep 14, 2010

New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa

A Phase 3 interventional study of sulfadoxine-pyrimethamine and Chloroquine in Malaria in Pregnancy, sponsored by Institute of Tropical Medicine, Belgium. Completed at 1 site in Burkina Faso. Open to female participants. Per ClinicalTrials.gov, last updated 2010-09-14.

Sponsored by Institute of Tropical Medicine, Belgium · Phase 3, Interventional, and Prevention

Phase
Phase 3
Study type
Interventional
Enrollment
2,766
Allocation
Randomized
Sex
Female
01

Study summary

Malaria in pregnancy contributes substantially to maternal anaemia and low birth weight: effective malaria control in pregnancy could avoid about 10,000 maternal and up to 200,000 infant deaths every year. Intermittent preventive treatment with the drug sulfadoxine-pyrimethamine (IPTp-SP), administered at least twice during routine antenatal clinics, is recommended by the World Health Organization for areas of moderate to high malaria transmission, including Sub-Saharan Africa.

Studies carried out in Kenya and Malawi before 2004 had showed that two doses of IPTp-SP significantly reduce maternal anaemia, placental malaria parasitaemia and low birth weight. However, in countries where this strategy had been introduced as part of national policy, the coverage of the target population has varied widely, with estimates of 33-93% for uptake of one dose and 24-68% for two doses, and no country had reached the goal of 80% of pregnant women receiving at least 2 doses of IPTp. New approaches designed to improve IPTp coverage were therefore urgently needed.

This study was therefore set up in 2002, in order to evaluate the additional effect of a targeted promotional campaign on antenatal clinics utilization and on coverage and uptake of Intermittent preventive treatment with sulfadoxine-pyrimethamine in a rural health district in Burkina Faso; and to investigate the effectiveness of intermittent preventive treatment with the sulfadoxine-pyrimethamine compared with weekly chloroquine, in order to provide additional evidence to the Burkinabé Ministry of Health for an impending policy change.

Read the detailed description

Each year, about 50 million women living in malaria endemic regions become pregnant, more than half in sub-Saharan Africa. In areas of relatively stable transmission, where acquired immunity to Plasmodium falciparum limits infection and prevents severe disease in adults, women in their first and second pregnancy are the most vulnerable subjects, due to a higher risk of severe anaemia and a low birth weight (LBW) outcome, a leading cause of child mortality and poor growth and development.

Malaria in pregnancy and its adverse consequences can be prevented with suppressive antimalarial treatment or chemoprophylaxis. Weekly chloroquine (CQ) had been the basis for prevention for many years, but its application became limited over time, partly because of difficulties in coverage and compliance throughout pregnancy and partly because of increased parasite resistance to CQ in endemic areas. A new strategy for prevention based on insecticide-treated bed nets (ITNs) and use of intermittent preventive treatment in pregnancy (IPTp) was thus formulated, with IPTp being based on the administration of treatment doses of sulfadoxine-pyrimethamine (1500/75 mg; SP) to all pregnant women at pre-defined intervals and regardless of malaria infection. WHO elaborated new recommendations, based on the administration of SP two or three times at scheduled antenatal visits at least one month apart from the second trimester onwards. Evidence of the efficacy of IPTp with SP for preventing malaria infection and improving birth weight was reported from East Africa and West Africa.

However, the IPTp strategy assumes that most pregnant women attend antenatal clinics (ANC) at least twice during their pregnancy and at a time when SP can be administered under direct observation. Unfortunately, it appeared soon that late attendance to ANC and weak health services limit the effectiveness of this strategy; coverage with two or more SP doses varied widely (24-68%) and was well behind the goal of 80% proposed by the Roll Back Malaria Partnership. New approaches to increase IPTp coverage were urgently needed.

This study, conceived in 2002 and carried out between 2004 and 2006, had therefore two different components: on one side, it investigated whether promoting regular and early antenatal attendance of pregnant women through community based health education would increase coverage and uptake of IPTp; on the other side, it investigated the effectiveness of IPTp-SP compared with weekly CQ, in order to provide additional evidence to the Burkinabé Ministry of Health for an impending policy change.

02

Conditions studied

  • Malaria in Pregnancy

Browse trials for

Keywords

  • Malaria
  • Pregnancy
  • Intermittent Preventive Treatment
03

In context

Malaria

1,299 studies on the registry are indexed under Malaria; 86 are open to participants now.

This study's enrollment of 2,766 is above the median of 220 across 1,027 interventional studies indexed under Malaria.

Browse Malaria studies →

Lead sponsor

Institute of Tropical Medicine, Belgium is the lead sponsor of 103 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Female
  • First or second trimester of pregnancy
  • First or second pregnancy
  • Resident in the study area

Exclusion criteria

Exclusion Criteria:

  • Refuse to give informed consent
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,766 participants (actual)

Study arms

  • Experimental
    1

    Experimental: IPTp-SP + promotion: Active Comparator

    Drug: sulfadoxine-pyrimethamine

  • Experimental
    2

    IPTp-SP alone (without promotion)

    Drug: sulfadoxine-pyrimethamine

  • Active comparator
    3

    Weekly CQ prophylaxis

    Drug: Chloroquine

Interventions

  • Drugsulfadoxine-pyrimethamine

    Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy

    Also known as: IPTp-SP, SP, Fansidar

  • DrugChloroquine

    Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week

    Also known as: CQ, Nivaquine

06

What researchers measure

Primary outcomes

  1. Birth weight

    Time frame: At delivery

Secondary outcomes

  1. Anemia

    Time frame: At 32 weeks gestation and at delivery

  2. Peripheral and placental parasitaemia

    Time frame: At 32 weeks gestation (peripheral) and at delivery (both)

  3. Gestational age

    Time frame: At first antenatal visit

07

Study locations

1 site
  • District Sanitaire
    Boromo, Burkina Faso
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 14, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00730366
Lead sponsor
Institute of Tropical Medicine, Belgium
Collaborators
University of Ouagadougou, Burkina Faso, National Laboratory of Public Health,Burkina Faso, Liverpool School of Tropical Medicine, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
First posted
Aug 8, 2008
Start date
Mar 2004
Primary completion
Oct 2006
Completion
Dec 2006
Last update
Sep 14, 2010

Study contacts

Sheick Coulibaly Oumar Coulibaly, MD PhD
study director · Directeur de la Biologie Médicale du Laboratoire National de Santé Publique
Umberto D'Alessandro, MD
study chair · Institute of Tropical Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion